{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:39Z","timestamp":1789609119044,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","award":["MA02210"],"award-info":[{"award-number":["MA02210"]}],"id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharmacy Therapeu"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1111\/jcpt.13642","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T02:50:08Z","timestamp":1647658208000},"page":"1081-1087","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ravulizumab 100 mg\/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome"],"prefix":"10.1155","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-0922","authenticated-orcid":false,"given":"Bradley P.","family":"Dixon","sequence":"first","affiliation":[{"name":"Renal Section Department of Pediatrics University of Colorado School of Medicine  Aurora Colorado USA"},{"name":"Children\u2019s Hospital Colorado  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-931X","authenticated-orcid":false,"given":"Ashley","family":"Sabus","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Colorado  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744\u20109987.12763"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.03.246"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2018.02.003"},{"key":"e_1_2_11_6_1","unstructured":"Alexion Pharmaceuticals I.SOLIRIS prescribing information."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012862.pub2"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.05.003"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.07.016"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.11.010"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019040331"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157\u2010018\u20101610\u20102"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157\u2010018\u20101609\u20108"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.07.011"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.034"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.026"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010050451"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_2_11_21_1","unstructured":"Alexion Pharmaceuticals I.ULTOMIRIS prescribing information."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.046"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010020\u201004774\u20102"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201009\u2010876805"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201009\u2010876136"},{"key":"e_1_2_11_27_1","unstructured":"AlexionPI.Alexion receives FDA approval for ULTOMIRIS\u00ae(ravulizumab\u2010cwvz) for atypical hemolytic uremic syndrome (aHUS).https:\/\/ir.alexion.com\/news\u2010releases\/news\u2010release\u2010details\/alexion\u2010receives\u2010fda\u2010approval\u2010ultomirisr\u2010ravulizumab\u2010cwvz. Accessed July 12 2021."},{"key":"e_1_2_11_28_1","unstructured":"AlexionPI.Alexion receives FDA approval for new advanced formulation of ULTOMIRIS\u00ae (ravulizumab\u2010cwvz) with significantly reduced infusion time.https:\/\/ir.alexion.com\/news\u2010releases\/news\u2010release\u2010details\/alexion\u2010receives\u2010fda\u2010approval\u2010new\u2010advanced\u2010formulation. Accessed July 7 2021."},{"key":"e_1_2_11_29_1","unstructured":"R\u00f6thA HillA AguzziR et al.An interim analysis of a phase 2 study evaluating the efficacy safety and pharmacokinetics of intravenous ravulizumab 100 mg\/mL formulation in patients with paroxysmal nocturnal hemoglobinuria. presented at: 25th Congress of the European Haematology Association; June 11\u201014 2020;"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2027706"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1831519"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","unstructured":"LevyACP TomazosI.Ravulizumab reduces productivity losses versus eculizumab for treating atypical hemolytic uremic syndrome: a \u2018cost consequence\u2019 analysis in 4 countries. presented at: ISPOR Europe 2020; 2020; Virtual.","DOI":"10.1016\/j.jval.2020.08.1769"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237497"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.13642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jcpt.13642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.13642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:35Z","timestamp":1671818735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.13642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/jcpt.13642"],"URL":"https:\/\/doi.org\/10.1111\/jcpt.13642","archive":["Portico"],"relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"value":"0269-4727","type":"print"},{"value":"1365-2710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"2021-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}